Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

ully in line with the results of the earlier Japanese studies," said Andrew R. Allen, executive vice president and chief medical officer of Pharmion Corporation. "We are pleased to see these exciting data reproduced in patients in the western hemisphere, as we expected, and we look forward to this pivotal trial and further investigating amrubicin's potential as a major advance for patients with small cell lung cancer."

About Amrubicin

Pharmion licensed the rights to amrubicin in November 2006. In 2002, amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of amrubicin.

About Small Cell Lung Cancer

Small cell lung cancer is a disease in which malignant cells form in the tissues of the lung, and which occurs almost exclusively in people who smoke. While small cell lung cancer constitutes approximately 15 percent of all lung cancers, SCLC tends to be more aggressive and fast growing than the more common non-small cell lung cancer. Of the estimated 62,000 patients diagnosed with SCLC each year in the US and EU, approximately 60 percent of patients have extensive disease at diagnosis, and the remaining 40 percent present with localized, or limited stage, disease.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that the company ... 2010 , after the market closes. The press release will be followed by ... to the public via telephone and webcast. During the conference call, the company ... , , ...
... RIVER, N.Y. , April 26 Netsmart Technologies, Inc., ... human services organizations, today named Lakeside Behavioral Healthcare of Orange ... Customer Innovation Award. , ... The Netsmart Customer Innovation Award recognizes organizations for their ...
Cached Medicine Technology:Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast 2Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 2Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 3Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 4Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 5
(Date:7/9/2014)... an innovative tool that captures heretofore hidden ways that ... a protein that makes breast cancer cells more likely ... trigger cancer,s spread in part by blocking two other ... that suggests these two disease processes could have unexpected ... July 10 issue of Nature , points to ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
(Date:7/9/2014)... 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at the ... July 17 in Copenhagen, Denmark. Data from the ... transition from cognitive normality to mild cognitive impairment and ... Aging Study , established in 1980 to examine healthy ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... City, July 9, 2014 A study published in ... De Koninck and Robert Bonin, two researchers at Universit ... hypersensitivity using a new method that involves rekindling pain ... could lead to novel means to alleviate chronic pain. ... Universit Laval and Institut universitaire en sant mentale de ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... -- an antibiotic being prescribed to people who may ... growth when taken by pregnant women. Instead, the Centers ... Cipro to pregnant women. The recommendation comes as health ... general population, possibly causing common bacteria to become resistant ...
... study, a trial of a new anti-cancer drug interacts ... a natural product, is being tested as an anti-cancer treatment. ... of the drug on the genes that are activated in ... affected by ceflatonin. These experiments have been done in human ...
... advertisements of prescription drugs, statements about drug benefits ... quantify the medications' expected benefit; instead, they make ... Medical School, Hanover, New Hampshire. // ... is that the medicine is going to prevent ...
... warn that gout can be incredibly painful, and if not ... belief, gout can strike at any time, and for no ... rich food and wine, and women can be affected too, ... affect middle-aged men and some people find an attack follows ...
... pregnant women at risk of the potentially fatal condition ... and E. ,The study, published in the Lancet, found ... pre-eclampsia. ,The condition involves the pregnant mother with ... of the unborn child through the placenta. ,Between ...
... who snore when they are pregnant may be at risk ... lives when they give birth. Around 10% of pregnant women ... can lead to injury or even death in the mother ... pressure by resting or with medication. But drugs may put ...
Cached Medicine News:Health News:Snoring could be a warning 2
... provides superior performance for the diagnosis ... that provides an answer in 6 ... will convince you of this tests ... deliver improved patient care with a ...
Shielding's Wrap-Around / Back Relief Apron transfers the weight from the shoulders to the waist with the aid of a 6" wide elastic belt. Belts may be ordered to fit various sized individuals....
... Shielding's Back Relief Apron has ... transfers the weight from the ... the aid of a 6" ... shoulder strap keeps apron snug. ...
Shielding's Velcro Adjustable Apron has two velcro flaps which aid in relieving weight off the shoulders. Its comfortable fit is attained by varying the position of flaps....
Medicine Products: